Sandbox:Hannan: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
Line 19: | Line 19: | ||
|Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of | |Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of | ||
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 | PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 | ||
* Myeloid/lymphoid neoplasms with PDGFRA rearrangement | * <small>Myeloid/lymphoid neoplasms with PDGFRA rearrangement</small> | ||
* Myeloid/lymphoid neoplasms with PDGFRB rearrangement | * <small>Myeloid/lymphoid neoplasms with PDGFRB rearrangement</small> | ||
* Myeloid/lymphoid neoplasms with FGFR1 rearrangement | * <small>Myeloid/lymphoid neoplasms with FGFR1 rearrangement</small> | ||
* Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK | * <small>Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK</small> | ||
| | | | ||
| | | | ||
Line 32: | Line 32: | ||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) | |Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) | ||
* Chronic myelomonocytic leukemia (CMML) | * <small>Chronic myelomonocytic leukemia (CMML)</small> | ||
* Atypical chronic myeloid leukemia (aCML), BCR-ABL1- | * <small>Atypical chronic myeloid leukemia (aCML), BCR-ABL1-</small> | ||
* Juvenile myelomonocytic leukemia (JMML) | * <small>Juvenile myelomonocytic leukemia (JMML)</small> | ||
* MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) | * <small>MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</small> | ||
* MDS/MPN, unclassifiable | * <small>MDS/MPN, unclassifiable</small> | ||
| | | | ||
| | | | ||
Line 46: | Line 46: | ||
|- | |- | ||
|Myelodysplastic syndromes (MDS) | |Myelodysplastic syndromes (MDS) | ||
* MDS with single lineage dysplasia | * <small>MDS with single lineage dysplasia</small> | ||
* MDS with ring sideroblasts (MDS-RS) | * <small>MDS with ring sideroblasts (MDS-RS)</small> | ||
* MDS-RS and single lineage dysplasia | * <small>MDS-RS and single lineage dysplasia</small> | ||
* MDS-RS and multilineage dysplasia | * <small>MDS-RS and multilineage dysplasia</small> | ||
* MDS with multilineage dysplasia | * <small>MDS with multilineage dysplasia</small> | ||
* MDS with excess blasts | * <small>MDS with excess blasts</small> | ||
* MDS with isolated del(5q) | * <small>MDS with isolated del(5q)</small> | ||
* MDS, unclassifiable | * <small>MDS, unclassifiable</small> | ||
* Provisional entity: Refractory cytopenia of childhood | * <small>Provisional entity: Refractory cytopenia of childhood</small> | ||
* Myeloid neoplasms with germ line predisposition | * <small>Myeloid neoplasms with germ line predisposition</small> | ||
| | | | ||
| | | | ||
Line 66: | Line 66: | ||
|Acute myeloid leukemia (AML) and related neoplasms | |Acute myeloid leukemia (AML) and related neoplasms | ||
* AML with recurrent genetic abnormalities | * AML with recurrent genetic abnormalities | ||
# AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 | # <small>AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1</small> | ||
# AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 | # <small>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11</small> | ||
# APL with PML-RARA | # <small>APL with PML-RARA</small> | ||
# AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A | # <small>AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A</small> | ||
# AML with t(6;9)(p23;q34.1);DEK-NUP214 | # <small>AML with t(6;9)(p23;q34.1);DEK-NUP214</small> | ||
# AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | # <small>AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM</small> | ||
# AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 | # <small>AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1</small> | ||
# Provisional entity: AML with BCR-ABL1 | # <small>Provisional entity: AML with BCR-ABL1</small> | ||
# AML with mutated NPM1 | # <small>AML with mutated NPM1</small> | ||
# AML with biallelic mutations of CEBPA | # <small>AML with biallelic mutations of CEBPA</small> | ||
# Provisional entity: AML with mutated RUNX1 | # <small>Provisional entity: AML</small> <small>with mutated RUNX1</small> | ||
* AML with myelodysplasia-related changes | * AML with myelodysplasia-related changes | ||
* Therapy-related myeloid neoplasms | * Therapy-related myeloid neoplasms | ||
* AML, NOS | * AML, NOS | ||
# AML with minimal differentiation | # <small>AML with minimal differentiation</small> | ||
# AML without maturation | # <small>AML without maturation</small> | ||
# AML with maturation | # <small>AML with maturation</small> | ||
# Acute myelomonocytic leukemia | # <small>Acute myelomonocytic leukemia</small> | ||
# Acute monoblastic/monocytic leukemia | # <small>Acute monoblastic/monocytic leukemia</small> | ||
# Pure erythroid leukemia | # <small>Pure erythroid leukemia</small> | ||
# Acute megakaryoblastic leukemia | # <small>Acute megakaryoblastic leukemia</small> | ||
# Acute basophilic leukemia | # <small>Acute basophilic leukemia</small> | ||
# Acute panmyelosis with myelofibrosis | # <small>Acute panmyelosis with myelofibrosis</small> | ||
* Myeloid sarcoma | * Myeloid sarcoma | ||
* Myeloid proliferations related to Down syndrome | * Myeloid proliferations related to Down syndrome | ||
# Transient abnormal myelopoiesis (TAM) | # <small>Transient abnormal myelopoiesis (TAM)</small> | ||
# Myeloid leukemia associated with Down syndrome | # <small>Myeloid leukemia associated with Down syndrome</small> | ||
| | | | ||
| | | | ||
Line 125: | Line 125: | ||
|- | |- | ||
|B-lymphoblastic leukemia/lymphoma | |B-lymphoblastic leukemia/lymphoma | ||
* B-lymphoblastic leukemia/lymphoma, NOS | * <small>B-lymphoblastic leukemia/lymphoma, NOS</small> | ||
* B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities | * <small>B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities</small> | ||
* B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 | * <small>B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1</small> | ||
* B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged | * <small>B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged</small> | ||
* B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1 | * <small>B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1</small> | ||
* B-lymphoblastic leukemia/lymphoma with hyperdiploidy | * <small>B-lymphoblastic leukemia/lymphoma with hyperdiploidy</small> | ||
* B-lymphoblastic leukemia/lymphoma with hypodiploidy | * <small>B-lymphoblastic leukemia/lymphoma with hypodiploidy</small> | ||
* B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH | * <small>B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH</small> | ||
* B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 | * <small>B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1</small> | ||
* Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like | * <small>Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like</small> | ||
* Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP | * <small>Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP</small> | ||
| | | | ||
| | | | ||
Line 145: | Line 145: | ||
|- | |- | ||
|T-lymphoblastic leukemia/lymphoma | |T-lymphoblastic leukemia/lymphoma | ||
* Provisional entity: Early T-cell precursor lymphoblastic leukemia | * <small>Provisional entity: Early T-cell precursor lymphoblastic leukemia</small> | ||
* Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph | * <small>Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph</small> | ||
| | | | ||
| | | |
Revision as of 12:44, 15 January 2019
Other myeloid neoplasm and acute leukemia | Clinical manifestations | Diagnosis | Other features | ||||
---|---|---|---|---|---|---|---|
Symptoms | Physical examination | Lab findings | Bone marrow biopsy | Gold standard | Other investigations | ||
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
|
|||||||
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
|
|||||||
Myelodysplastic syndromes (MDS)
|
|||||||
Acute myeloid leukemia (AML) and related neoplasms
|
|||||||
Blastic plasmacytoid dendritic cell neoplasm | |||||||
Acute leukemias of ambiguous lineage
|
|||||||
B-lymphoblastic leukemia/lymphoma
|
|||||||
T-lymphoblastic leukemia/lymphoma
|
(CML), BCR-ABL1+
- prefibrotic/early stage
- overt fibrotic stage